Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China

Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. This study aimed to investigate the lifetime cost-effective value of IDegLira compared with its single component (Degludec or Liraglutide) and to ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Guangxin, Hu, Shanshan, Zhang, Xiaoning, Qiu, Zhikun, Huang, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716023/
https://www.ncbi.nlm.nih.gov/pubmed/36467033
http://dx.doi.org/10.3389/fphar.2022.1011624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716023/
https://www.ncbi.nlm.nih.gov/pubmed/36467033
http://dx.doi.org/10.3389/fphar.2022.1011624

Ejemplares similares